Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99646 | 0.88 | CA12 (0.65) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL1585896 | 0.81 | CA12 (0.59) | CA12CA1CA2CA9KMT2A | |
| Water SCHEMBL11215220 | 0.79 | CA12 (0.57) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL6294350 | 0.78 | MEN1 (0.42) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL3395424 | 0.77 | CA12 (0.55) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL174596 | 0.77 | CA1 (0.55) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL7717454 | 0.77 | CA1 (0.55) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL2297932 | 0.77 | CA12 (0.55) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL2281904 | 0.77 | CA12 (0.55) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL170694 | 0.77 | MAPT (0.56) | CA12CA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798090-A | Palladium-catalyzed synthesis method of N-monoallylamine derivative | 深圳职业技术大学 | 2025-04-11 | — | — | CN | disclosed |
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| EP-1706413-A1 | TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005068472-A1 | TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-07-28 | — | — | WO | disclosed |
| US-5712414-A | Hydroxycarboxylic acid anilides | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-01-27 | — | — | US | disclosed |
| EP-0753507-A1 | Process for the preparation of hydroxycarboxylic acid anilides | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-01-15 | — | — | EP | disclosed |
| US-4767868-A | 3-Phenyl-3-(1H-imidazol-1-ylmethyl)-2-methyl-5-[(phenylamino)methyl]isoxazolidines | PENNWALT CORPORATION (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0257391-A2 | 5-Substituted-3-phenyl-3-(1H-imidazol-1-ylmethyl)-2-methylisoxazolidines | FISONS CORPORATION (US) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | CACNA1I, HDAC3, AADAC | CA12 4520/4885CA1 3990/4885CA2 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.